Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
NCT04796012Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in solid tumor, rhabdomyosarcoma (RMS), sponsored by UT Southwestern Medical Center. Started Apr 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
solid tumorrhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04796012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796012.